Aquestive Therapeutics, Inc. (AQST)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aquestive Therapeutics, Inc. ("Aquestive" or "the Company") (NASDAQ: AQST). The investigation concerns whether Aquestive and certain of its officers and/or directors have violated federal securities laws.
On September 25, 2020, Aquestive announced receipt of a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) “regarding the New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film for management of seizure clusters.” Aquestive advised investors that “[i]n the CRL, the FDA cited that, in a study submitted by the Company with the NDA, certain weight groups showed a lower drug exposure level than desired. The Company intends to provide to the FDA additional information on PK modeling to demonstrate that dose adjustments will obtain the desired exposure levels.” On this news, Aquestive’s stock price fell $2.64 per share, or 34.69%, to close at $4.97 per share on September 28, 2020.
If you are aware of any facts relating to this investigation, or purchased Aquestive shares, you can assist this investigation by contacting the firm. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.